The role of mutations in epigenetic regulators in myeloid malignancies
- PMID: 22898539
- DOI: 10.1038/nrc3343
The role of mutations in epigenetic regulators in myeloid malignancies
Abstract
Recent genomic studies have identified novel recurrent somatic mutations in patients with myeloid malignancies, including myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). In some cases these mutations occur in genes with known roles in regulating chromatin and/or methylation states in haematopoietic progenitors, and in other cases genetic and functional studies have elucidated a role for specific mutations in altering epigenetic patterning in myeloid malignancies. In this Review we discuss recent genetic and functional data implicating mutations in epigenetic modifiers, including tet methylcytosine dioxygenase 2 (TET2), isocitrate dehydrogenase 1 (IDH1), IDH2, additional sex combs-like 1 (ASXL1), enhancer of zeste homologue 2 (EZH2) and DNA methyltransferase 3A (DNMT3A), in the pathogenesis of MPN, MDS and AML, and discuss how this knowledge is leading to novel clinical, biological and therapeutic insights.
Similar articles
-
The Impact of Epigenetic Modifications in Myeloid Malignancies.Int J Mol Sci. 2021 May 9;22(9):5013. doi: 10.3390/ijms22095013. Int J Mol Sci. 2021. PMID: 34065087 Free PMC article. Review.
-
[Research on molecular markers for epigenetic changes in myeloid malignancies].Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2013 Dec;30(6):687-92. doi: 10.3760/cma.j.issn.1003-9406.2013.06.012. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2013. PMID: 24327148 Review. Chinese.
-
Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.J Exp Med. 2013 Nov 18;210(12):2627-39. doi: 10.1084/jem.20131144. Epub 2013 Nov 11. J Exp Med. 2013. PMID: 24218139 Free PMC article.
-
A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1-negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia-related.Int J Lab Hematol. 2024 Aug;46(4):687-694. doi: 10.1111/ijlh.14280. Epub 2024 Apr 26. Int J Lab Hematol. 2024. PMID: 38665121
-
Mutations in epigenetic regulators in myelodysplastic syndromes.Int J Hematol. 2012 Jan;95(1):8-16. doi: 10.1007/s12185-011-0996-3. Epub 2012 Jan 11. Int J Hematol. 2012. PMID: 22234528 Review.
Cited by
-
Epigenetic control of myeloid cell differentiation, identity and function.Nat Rev Immunol. 2015 Jan;15(1):7-17. doi: 10.1038/nri3777. Nat Rev Immunol. 2015. PMID: 25534619 Review.
-
Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas.Brain Pathol. 2013 Sep;23(5):558-64. doi: 10.1111/bpa.12042. Epub 2013 Mar 6. Brain Pathol. 2013. PMID: 23414300 Free PMC article.
-
The B cell transcription program mediates hypomethylation and overexpression of key genes in Epstein-Barr virus-associated proliferative conversion.Genome Biol. 2013 Jan 15;14(1):R3. doi: 10.1186/gb-2013-14-1-r3. Genome Biol. 2013. PMID: 23320978 Free PMC article.
-
Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms.Cancers (Basel). 2021 Apr 27;13(9):2120. doi: 10.3390/cancers13092120. Cancers (Basel). 2021. PMID: 33925681 Free PMC article. Review.
-
Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma.Leukemia. 2015 Oct;29(10):2113-6. doi: 10.1038/leu.2015.81. Epub 2015 Mar 19. Leukemia. 2015. PMID: 25787914 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous